Professor Richard T. Bryan MBChB, PhD, MRCS, FAcadTM

Professor Richard T Bryan

Department of Cancer and Genomic Sciences
Director of the Bladder Cancer Research Centre
Professor in Urothelial Cancer Research

Contact details

Address
Department of Cancer and Genomic Sciences
Robert Aitken Institute for Clinical Research
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Rik Bryan is a former clinical urologist, and now a full-time bladder cancer research academic. He is the Chief Investigator of the Bladder Cancer Prognosis Programme (BCPP), the SELENIB clinical trial, and POUT-T. He is the Director of the Bladder Cancer Research Centre (BCRC) in the Department of Cancer and Genomic Sciences. The BCRC has a particular interest in the proteomics, genomics and epigenomics of bladder cancer and related biomarkers, and novel agents, technologies and pathways.

Qualifications

  • Fellow of the Academy of Translational Medicine 2016
  • PhD in Medicine 2007
  • Membership of The Royal College of Surgeons of England 1999
  • MBChB 1995

Biography

Rik Bryan qualified in Medicine at the University of Birmingham and subsequently entered surgical training. After completing a PhD in bladder cancer biology he became a higher surgical trainee in Urology. After 4-years as a Specialist Registrar, Rik left clinical urology to assist with the set-up of the Bladder Cancer Prognosis Programme (BCPP) in the Department of Public Health, Epidemiology and Biostatistics at the University of Birmingham, and was then subsequently appointed as a Senior Research Fellow in the School of Cancer Sciences. Rik is now the Chief Investigator of BCPP, which incorporates the SELENIB clinical trial.

Rik has an interest in all aspects of bladder cancer research and directs the Bladder Cancer Research Centre (BCRC) with a focus on translation. The particular interests of the BCRC include cancer proteomics/genomics/epigenomics, urinary biomarkers, novel therapeutics/technologies/devices, and clinical and epidemiological research. Rik has a track record of publication in all of these areas.

The BCRC also has an interest in upper tract urothelial cancer, and Rik is the Chief Investigator of POUT-T, the translational study linked to the POUT trial.

Postgraduate supervision

  • Intercalated BMedSci
  • MRes
  • PhD

Research

  • Genomics and epigenomics, and associated biomarkers for non-invasive diagnosis and prognostication
  • Novel genomic platforms and approaches
  • Proteomics and urinary protein biomarkers
  • Novel therapeutics, technologies and devices and associated clinical trials
  • Tumour immunology and BCG mechanisms of action
  • Clinical, epidemiological and health economic research.

Aside from the research carried out at the University of Birmingham, the Bladder Cancer Group also has a number of important national and international collaborations with other bladder cancer investigators, including Professor Maurice Zeegers (Maastricht), Professor John Kelly (UCL), Professor Bart Kiemeney (Radboud), Professor Chris Probert (Liverpool), Dr Anne Kiltie (Oxford) and Professor Chas Bountra (Oxford).

Other activities

Aside from his bladder cancer research at the University of Birmingham, Rik also fulfils a number of other roles:

  • Member of the University of Birmingham’s Clinical Trials Oversight Committee (CTOC)
  • Member of the Bladder GeCIP, 100,000 Genomes Project
  • Trustee of the charity Action Bladder Cancer UK
  • Member of the T2 and Below Subgroup (TABS) of the NCRI Bladder & Renal Clinical Studies Group
  • Council Member and current Honorary Secretary of The Royal Society of Medicine Section of Urology
  • Member of the Trial Management Group of the Peri-Operative Chemotherapy versus Surveillance in Upper Tract Urothelial Cancer (POUT) trial
  • Member of the Trial Management Group of the Clinical Research Office of the Endourology Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection (TURBT) versus conventional white light-assisted TURBT in primary non-muscle-invasive bladder cancer patients.

Publications

Recent publications

Article

Saeed, AK, Triantafyllakis, P, Gordon, NS, James, ND, Zeegers, MP, Cheng, KK, Bryan, RT & Ward, DG 2026, 'ADAM17 drives HAI-1 ectodomain release in bladder cancer with HAI-1 loss promoting aggressive in vitro behaviour', FEBS Letters.

Hof, JP, Galesloot, TE, Aben, KKH, Bryan, RT, Catto, JWF, Cheng, KK, Conroy, S, Fleshner, NE, van der Heijden, AG, James, ND, Mengual, L, Uunk, FM, Verhaegh, G, Vrieling, A, Zeegers, MP, Kiemeney, LALM & Vermeulen, SH 2026, 'Comprehensive genome-wide association study into multiple recurrence and progression risk in non-muscle invasive bladder cancer', Cancer Genetics, vol. 306-307, pp. 106-115. https://doi.org/10.1016/j.cancergen.2026.06.004

Neil, JL, Gordon, NS, Goel, A, Myumyun, AN, Tura, B, de Jong, JJ, Davicioni, E, Zeegers, MP, Cheng, KK, James, ND, Neou, M, Arnold, R, Bryan, RT & Ward, DG 2026, 'Development of an extended version of GALEAS bladder: Detection of FGFR3 fusions in urine and associations between genomic alterations and gene expression', Bladder Cancer, vol. 12, no. 2, 23523735261447112. https://doi.org/10.1177/23523735261447112

Gao, J, Murray, BO, Wu, Q, Fryer, MT, Hubbard, ATM, Bryan, RT, Stride, E & Rohn, JL 2026, 'Evaluation of a rapid-release mitomycin C-loaded porous microcapsule formulation (MitoCap) in a human urothelium-tumour model', International Journal of Pharmaceutics. https://doi.org/10.1016/j.ijpharm.2026.127429

Collett, G, Johnstone, K, Bashford, T, Proud, W, Tazi, M, Van Hemelrijck, M, Bryan, RT & Fry, BG 2026, 'From Blast to Biological Uptake: Residual Dinitrotoluene as an Occupational Exposure Hazard in Explosive Ordnance Disposal', Toxics, vol. 14, no. 9, 812. https://doi.org/10.3390/toxics14090812

Chen, Y-T, Sui, J, Yang, Y, Zhang, H, Wesselius, A, Shen, Y, Qin, Q-R, Sun, G-J, Wang, S-K, Wang, X-D, Wang, S, Li, W-C, Cheng, KK, James, ND, Bryan, RT, Zeegers, MP, Chen, L, Xia, H & Yu, EY-W 2026, 'Integration of gut microbiome and lipid metabolism reveals the anti-cancer effects of pentadecanoic acid on bladder cancer', BMC medicine, vol. 24, no. 1, 10. https://doi.org/10.1186/s12916-025-04554-5

Bryan, R 2026, 'INTERACT - Understanding inclusivity in oncology clinical trials using a data-driven approach: protocol for a retrospective observational study and service evaluation', BMJ Open.

Bryan, RT, Goel, A & Ward, DG 2026, 'PENK methylation and non-invasive bladder cancer detection', Translational Andrology and Urology, vol. 15, no. 4, 96. https://doi.org/10.21037/tau-2026-1-0128

de Jong, JJ, Moreno-Oya, A, Olislagers, M, de Jong, FC, Lindskrog, SV, Goel, A, Arnold, R, Bryan, RT, Eriksson, P, Sjödahl, G, Akand, M, Baekelandt, L, Zuiverloon, TCM, Rinaldetti, S & Nakauma-Gonzalez, JA 2026, 'Proceedings of the first international NMIBC consensus classification meeting', Bladder Cancer, vol. 12, no. 2. https://doi.org/10.1177/23523735261417949

Dai, YN, Tura, B, Yu, EYW, Zeegers, MP, Cheng, KK, James, ND, Bryan, RT & Wesselius, A 2026, 'Pro-inflammatory diet predicts poorer survival in bladder cancer: Results from the bladder cancer prognosis programme', Clinical Nutrition, vol. 62, 106679. https://doi.org/10.1016/j.clnu.2026.106679

Gao, J, Ji, CX, Ren, C, Hines, J, Stride, E, Bryan, RT & Rohn, JL 2026, 'Rapid normal fibroblast-tumor crosstalk promotes cancer-associated fibroblast-like activation and attenuates mitomycin C cytotoxicity in bladder cancer', Journal of Cell Communication and Signaling, vol. 20, no. 3, e70110. https://doi.org/10.1002/ccs3.70110

Silcock, L, Hastings, RK, Clokie, S, Sadler, R, Parks, M, Smith, M, Hewitt, V, Douglas-Moore, JL, Wignall, H, Escabelado, H, Piedad, J, Kanabar, S, Blick, C, Mohee, A, Pumfrey, N, Coull, N, Goffe, A, Tippett, R, Laird, A, Shah, CP, MacKay, M, Owen, C, Mufti, U, Ward, DG & Bryan, RT 2026, 'Real-World Multicentre Evaluation of GALEAS Bladder for Detecting Bladder Cancer in UK NHS Haematuria Clinics', European Urology Oncology. https://doi.org/10.1016/j.euo.2026.08.005

Comment/debate

Ward, DG, Silcock, L, Douglas-Moore, JL & Bryan, RT 2026, 'Evolution or revolution — the GALEAS Bladder molecular urine test for triaging patients with haematuria', Nature Reviews Urology. https://doi.org/10.1038/s41585-026-01196-x

Letter

Humayun-Zakaria, N, Tura, BJ, van Hemelrijck, M & Bryan, RT 2026, 'Aligning Bladder Cancer Research with Patient Needs: an update on research priorities', BJU international. https://doi.org/10.1111/bju.70206

Ye, T, Tura, B, Abbotts, B, Zeegers, MP, Cheng, KK, James, ND & Bryan, RT 2026, 'Clinical outcomes of BCG-treated patients with high-risk non-muscle-invasive bladder cancer according to pre- and post-2021 European Association of Urology risk classifications', BJU international. https://doi.org/10.1111/bju.70247

View all publications in research portal

Expertise

Bladder Cancer